This study showed that the frequency of NSE values above the reference value (≥12 ng/mL) in the blood-donor group (16.7%) was comparable to the frequency of NSE in both the T2DM group before COVID-19 (13.8%) and the NfT2DM group before COVID-19 (12.0%). This evidence concerns the gene ENO2 and type 2 diabetes mellitus.